130 likes | 224 Views
HIVI. HIV Initiative of Kaiser Permanente and Care Management Institute. Barriers and Facilitations to HIV Testing in Private Care Settings. Michael Horberg, MD MAS FACP Director, HIV/AIDS Kaiser Permanente Clinical Lead, HIV/AIDS, Care Management Institute.
E N D
HIVI HIV Initiative of Kaiser Permanente and Care Management Institute Barriers and Facilitations to HIV Testing in Private Care Settings Michael Horberg, MD MAS FACP Director, HIV/AIDS Kaiser Permanente Clinical Lead, HIV/AIDS, Care Management Institute
Conflicting National Guidelines (1) • CDC Guidelines Routine testing of all Americans aged 13-64 However, no consideration of older Americans and risk assessment • USPSTF Guidelines No recommendation for routine testing (C Level) Recommend at-risk testing (A Level) All pregnant women (A Level) Evidence-based but too restrictive Slide 2
Conflicting National Guidelines (2) • Private insurers usually defer to USPSTF • Some insurers are developing own guidelines • KP is bridge of USPSTF and CDC • Professional societies are not uniform in opinion • ACP, IDSA, AMA, ACOG, AAP support CDC • AAFP does not recommend routine testing of all Slide 3
Statutes as Barriers • Written informed consent considered hardship by providers • Time consuming, burdensome • Not for other sexually transmitted infections or routine blood tests • Laws changing • 40+ states and DC no longer require written consent • Only California and DC mandate coverage of testing costs Slide 4
Lack of Quality Metrics • No nationally accepted metric on HIV testing • None in HEDIS, AMA PQRI • VA and KP measure stage of disease at time of diagnosis • There are HIV care metrics • (see next slide) • Many have called for HIV testing measurements Slide 5
No HIV diagnosis or access to care measure Other Screening Measures TB, gonorrhea/chlamydia, syphilis Hepatitis B and C High risk sexual behavior Substance use Process Measures Retention in care CD4 cell count Appropriate PCP prophylaxis and ART Influenza, Pneumococcus, and Hepatitis B immunization Outcome Measures HIV RNA control AMA/HIVMA/HRSA/NCQA Measures Slide 6
Reimbursement Issues (1) • Targeted testing has not been an issue • Cost of test vs. cost of testing • Some issues with routine testing reimbursement • Many insurance companies have relaxed reimbursement policy • Don’t usually look at HIV risk when handling claim • AMA and AAHIVM published guidelines for coding for testing and services Slide 7
Reimbursement Issues (2) • CMS now covering targeted HIV testing • Thought will cover most patients at risk • Recognizes increased sexual activity among older adults • Anticipated that private insurers will follow suit • Unclear how CMS changes affect Medicaid • Preventive services included in healthcare reform • Again, California and DC mandate coverage Slide 8
KP HIV Demographics--Overview Largest private provider of HIV care in US >19,000 in 2009 regional variation (~200 to >6500) Demographics reflect states we serve Aging, but not dying Mortality 1.6%--less than national average (3.4%) Employ a multi-disciplinary specialty model Slide 9
KP HIV Testing (1) • Performs >340,000 HIV tests annually • <25% of our total patient population • 55.8% tested for HIV if diagnosed with STI • However, 43.4% if include Hepatitis B/C • 27.1% new HIV+ met AIDS criteria (CD4 <200/µL) • 87-96% prenatal testing rates • All of these numbers are improving Slide 10
KP HIV Testing (2) Slide 11
KP HIV Testing Quality Improvement Expanded HIV testing guidelines • More universal but targets at-risk populations • Especially patients diagnosed with STI • No upper age limits • All pregnant women (and consideration of continued risk during pregnancy) • Looking to expand • Include Adolescents • Include evidence-based counseling and prevention Slide 12
Access to Care and Outcomes (KP) 2007 data: • 88.6% newly recognized HIV+ in care within 90 days • 76.8% retention in care • 86.8% appropriately given ART • Median adherence 93.8% HIV+ on ART • 92.9% HIV+ on ART with maximal viral control Slide 13